Capital Raising
OPEN
ReGen Factor
Revolutionizing Healing with Bio-Identical Growth Factors and Advanced RNA Technologies
INDUSTRY
Biotech & Life Sciences
RAISING
A$6M
PRE-MONEY VALUATION
A$36M
MINIMUM INVESTMENT
A$25,000
Investment Highlights
Company Overview
Products & Services
Transaction Overview
Team
News
Transaction Summary
ReGen Factor
Raising A$6M
$36M Pre-Money Valuation
$25,000 minimum investment
Investment Highlights
Revolutionary Technology: ReGen Factor’s proprietary bio-identical fibroblast growth factor (bFGF) represents a groundbreaking leap in regenerative medicine, stimulating natural cell growth, tissue repair, and regeneration with unmatched safety and efficacy.
Why Bio-Identical is Special: Most competitors rely on synthetic or modified proteins, risking immune responses or reduced potency. ReGen Factor’s bio-identical technology mirrors the body’s natural processes, ensuring superior performance and patient outcomes.
Dominating a High-Growth Market: The global regenerative medicine market, valued at $25B in 2022, is projected to reach $125B by 2030, driven by advancements like ReGen Factor’s bio-identical bFGF and emerging RNA-based therapies.
Proven Success and Tangible Results:
With over 30,000 PepFactor treatments worldwide:
- 92% success rate in hair regrowth.
- 99% success rate in skin rejuvenation.
- 99% success rate in acne treatments.
- 99% success rate in acne scar revision.
- These figures validate the clinical impact and market demand for ReGen Factor’s therapies.
Scalable, Cost-Effective Innovation: ReGen Factor’s proprietary yeast-based production method delivers bio-identical bFGF at a fraction of traditional costs, ensuring scalability and affordability for global markets.
Impacting Lives and Delivering Returns: By integrating cutting-edge science with real-world applications, ReGen Factor offers a rare opportunity to back a transformative technology with extraordinary financial and societal potential.
Company Overview
Transforming Healthcare Through Innovation
ReGen Factor is revolutionizing regenerative medicine with proprietary bio-identical fibroblast growth factors (bFGFs) that redefine the standard of care across multiple therapeutic areas.
Addressing a $125B Market Opportunity
From wound healing to cosmeceuticals, ReGen Factor targets critical healthcare needs in one of the fastest-growing sectors, projected to exceed $125B by 2030.
Global Market Presence and Scalability
With established distribution channels across Australia, USA, UK, and Poland, ReGen Factor is strategically positioned to scale rapidly and dominate the global market.
Proven Expertise and Market Validation
Backed by 30,000+ successful treatments and unmatched success rates, ReGen Factor’s cutting-edge solutions are already transforming lives worldwide.
ReGen Factor Pty Ltd is a trailblazing Australian biotech company dedicated to reshaping the future of healthcare. At the core of our innovation is bio-identical fibroblast growth factor (bFGF) technology, a natural and precise solution that accelerates healing, enhances skin and hair rejuvenation, and addresses chronic health challenges. By perfectly replicating the body’s own healing proteins, our technology ensures superior safety and efficacy, outpacing traditional and synthetic alternatives.
With a proven track record of 30,000+ successful PepFactor treatments, ReGen Factor has already achieved remarkable success in treating hair loss (92% efficacy) and skin rejuvenation (99% efficacy). These results provide a solid foundation for scaling our products globally.
The company’s robust pipeline spans regenerative medicine, cosmeceuticals, and advanced gene therapy platforms, addressing critical healthcare needs and unmet market demands. As a pioneer in regenerative medicine, ReGen Factor is uniquely positioned to seize a significant share of the $125B global market.
Why ReGen Factor?
- Innovation That Matters: Our bio-identical bFGF technology represents a paradigm shift in regenerative solutions.
- Global Scalability: With established distribution channels across key markets, we’re ready to deliver solutions to millions.
- Proven and Reliable: Unmatched clinical success demonstrates both safety and market acceptance.
- Sustainability in Growth: Scalable, cost-effective production processes ensure our products remain accessible without compromising quality.
ReGen Factor is not just a company—it’s a catalyst for global healthcare transformation. By merging science, technology, and compassion, we are delivering solutions that improve lives while creating immense value for our stakeholders.
Previous Funding
Between 2022 and 2023, ReGen Factor successfully raised $1M at $0.05 per share, demonstrating strong investor confidence in our groundbreaking technology and market potential.
Notable Investors:
Our investor base includes visionary private individuals and family offices with a strategic focus on the healthcare sector. These early supporters recognized the transformative power of ReGen Factor’s bio-identical fibroblast growth factor (bFGF) technology and its potential to dominate the $125B regenerative medicine market.
This milestone capital raise enabled critical advancements in product development, regulatory preparation, and global distribution expansion, laying a solid foundation for the next phase of growth and innovation.
Product Portfolio
ReGen Factor’s product portfolio represents the pinnacle of innovation in regenerative medicine, offering cutting-edge solutions that deliver exceptional results across multiple therapeutic and cosmetic applications:
PepFactor Scalp
Revolutionary scalp rejuvenation therapy with a 92% success rate in restoring hair growth.
PepFactor Skin
Advanced skin therapy achieving a 99% success rate in reducing wrinkles and acne, leaving skin youthful and radiant.
WoundCare
A game-changing solution for diabetic ulcers and chronic wounds, promoting visible healing within 45 days.
ReGenFactorX
A cutting-edge gene expression platform unlocking regenerative solutions for diabetes and tissue degeneration.
AcneVitus
A next-generation acne treatment tackling inflammatory pathways to deliver clearer, healthier skin.Why Choose ReGen Factor Products?
Each product is powered by bio-identical fibroblast growth factor (bFGF) technology, ensuring unmatched safety, efficacy, and results. Whether for hair restoration, skincare, wound healing, or advanced therapies, ReGen Factor’s solutions are designed to transform lives, setting a new standard in regenerative medicine.
This carefully curated product range represents the forefront of innovation, backed by proven results and positioned to dominate in a multi-billion-dollar global market.
Strategic Facility and Revenue Impact
Facility Overview:
ReGen Factor has secured a 600m² GMP-compliant facility at Daydream Street, Warriewood, with council approval for an additional 100m² mezzanine expansion. This state-of-the-art facility will serve as:
- An R&D Hub: Driving innovation in regenerative medicine.
- A Production Center: Scaling manufacturing to meet global demand.
- A Distribution Node: Supporting seamless global product delivery.
Projected ROI and Revenue Impact:
- Revenue Generation: Facility supports production of 100,000+ units annually, projected to generate AUD $50M in annual revenue by 2027.
- Cost Savings: In-house manufacturing reduces production costs by 30%-50%, significantly boosting profit margins.
- Patent Value Addition: RNA patents unlock high-value applications in oncology and gene therapies, contributing an estimated AUD $15M in incremental annual revenue by 2028.
Strategic Value: Owning and operating a facility of this caliber significantly enhances ReGen Factor’s valuation, contributing to the projected growth from AUD $36M (pre-money) to AUD $100M+ post-IPO in 2025 and AUD $200M+ post-Nasdaq listing by 2027.
Risk Management Strategy
Regulatory Pathways:
- Leveraging established precedents for FDA and TGA-approved growth factor therapies.
- Close collaboration with regulatory authorities ensures compliance and expedites approval processes.
Competitive Differentiation:
- Securing exclusive patents and proprietary production methods shields ReGen Factor from competitive risks.
- Emphasizing superior safety, efficacy, and cost-efficiency positions the company as a leader in regenerative medicine.
Market Adoption:
- Demonstrated success of 30,000+ PepFactor treatments minimizes market adoption risk.
- Established distribution channels across the USA, UK, and Australia ensure efficient market penetration.
Transaction Overview
Raising up to A$6M on a Pre-Money valuation of A$36M
Minimum investment of A$25,000
Over A$1M raised to date
Use of Funds
R&D | Plant & Equipment | Administration | Marketing / Other |
|---|---|---|---|
22%
Fill Counter
| 42.5%
Fill Counter
| 10%
Fill Counter
| 56%
Fill Counter
|
Conclusion
ReGen Factor is redefining healthcare through unparalleled innovation and operational excellence. The secured facility at Warriewood, coupled with its patented bio-identical and RNA technologies, positions the company to dominate the $125B regenerative medicine market. With clear risk mitigation strategies, robust financial potential, and proven success, this is a unique opportunity to join a biotech revolution that is transforming lives globally.
Additional Information
Team
General Disclaimer
The content on this site is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security and is not warranted to be correct, complete or accurate. This site is intended for Accredited/Sophisticated/Wholesale investors only. By continuing with an investment, you are self-accrediting that you so qualify. To the extent permitted by law, neither PrimaryMarkets, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment opportunities on this site and any statements made about them by their issuers are not vetted or verified by PrimaryMarkets. Investing in securities in private or unlisted companies and Funds is speculative and involves a high degree of risk. The investor must be prepared to withstand a total loss of their investment. We strongly encourage the investor to seek independent financial, professional or investment advice before investing in securities. The presence of an investment opportunities on this site should not be interpreted as an implied endorsement of it by PrimaryMarkets. Some content provided may constitute a summary or extract of another document. Past performance does not necessarily indicate future performance. The content on this site was current as at date of initial publication but may not be current as at the date of your viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.
Want to learn more?
Fill in the expression of interest form below
Newsletter Subscription
Corporate Solutions
About
Solutions
Level 6, 56 Pitt Street, Sydney NSW 2000 Australia
2024 © PrimaryMarkets Pty Ltd.
All Rights Reserved
Corporate Authorised Representative: AFSL 485 946 Level 6, 56 Pitt St Sydney P: +61 2 9993 4475
